Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

2018 Ofatumumab (Genmab/Novartis) Drug Analysis Report -

Research and Markets
Posted on: 19 Feb 18

The "Drug Analysis: Ofatumumab" drug pipelines has been added to's offering.

Ofatumumab (Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation (CD)20 on the B-cell membrane. Ofatumumab binds effectively to both the small and large extracellular loops on CD20 and releases very slowly over time. Preclinical and clinical data have demonstrated that ofatumumab effectively depletes B cells, some of the major cells involved in the autoimmune responses seen in multiple sclerosis (MS). Being a fully human monoclonal antibody, ofatumumab also shows potential for low immunogenicity, and its efficacy is less likely to diminish during prolonged treatment.

Ofatumumab was originally developed by Genmab, and is currently marketed and developed in collaboration with Novartis. Ofatumumab is already approved for the treatment of chronic lymphocytic leukemia in both the US and Europe, where it is marketed as Arzerra. In MS, the drug entered Phase III development in September 2016. Novartis is conducting ofatumumab's pivotal studies in relapsing MS, and the company plans to file for approval in 2019.

Key Topics Covered:

List of Figures

Figure 1: Ofatumumab for multiple sclerosis - SWOT analysis

Figure 2: Drug assessment summary of ofatumumab for multiple sclerosis

Figure 3: Drug assessment summary of ofatumumab for multiple sclerosis

List of Tables

Table 1: Ofatumumab drug profile

Table 2: Ofatumumab Phase III trials in multiple sclerosis

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 19/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.